Elsevier

The Lancet

Volume 335, Issue 8700, 26 May 1990, Page 1289
The Lancet

LETTERS to the EDITOR
Dystrophin function

https://doi.org/10.1016/0140-6736(90)91364-GGet rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (17)

  • Pharmacological advances for treatment in Duchenne muscular dystrophy

    2017, Current Opinion in Pharmacology
    Citation Excerpt :

    Absence of dystrophin and subsequent loss of the DAPC leads to progressive defects including perturbation of the calcium homeostasis, activation of proteases and pro-inflammatory cytokines, and mitochondrial dysfunction resulting in continual influx of inflammation, fibrosis, repeated cycles of necrosis and altered regeneration, with impaired vascular adaptation (Figure 1). The myofibres become more susceptible to contraction-induced injury, which results in premature death, muscle wasting and fatty tissue replacement [6]. Despite exhaustive clinical management and corticosteroid treatment, there is currently no effective treatment for DMD, although considerable progress has been made recently in genetic approaches [7,8].

  • Chapter 9 The Value of Mammalian Models for Duchenne Muscular Dystrophy in Developing Therapeutic Strategies

    2008, Current Topics in Developmental Biology
    Citation Excerpt :

    Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by X-linked recessive mutations in the dystrophin gene (Chamberlain, 1991; Chamberlain and Rando, 2006; Emery, 1990; Engel and Franzini-Armstrong, 2004).

View all citing articles on Scopus
View full text